Clinical Research Directory
Browse clinical research sites, groups, and studies.
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
Sponsor: Boston University Charles River Campus
Summary
The purpose of this study is to investigate the efficacy of d-cycloserine (DCS) treatment for Gulf War Illness (GWI). Gulf War veterans with Gulf War Illness experience numerous chronic health symptoms, including cognition and fatigue, which reduces their quality of life. Gulf War veterans are in urgent need of novel treatment plans to tackle elusive symptomatology of Gulf War Illness. By using the literature of previous studies, the investigators have chosen to investigate d-cycloserine as a possible candidate for treating GWI, specifically cognitive symptoms. DCS has been shown to reduce neuroinflammation, regulate glutamate levels, and improve synaptic functioning in key areas of the brain.
Official title: D-cycloserine: A Novel Treatment for Gulf War Illness
Key Details
Gender
All
Age Range
43 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2015-10
Completion Date
2019-09-15
Last Updated
2026-09-09
Healthy Volunteers
No
Conditions
Interventions
D-cycloserine
100mg of DCS will be administered orally in pill form daily for 4 weeks
Placebo
A placebo will be administered orally daily for 4 weeks
Locations (1)
Boston University
Boston, Massachusetts, United States